R-Zero, a San Francisco, CA-based biosafety technology company dedicated to reducing the spread of infectious disease, raised $41.5m in Series B funding.
The round, which brought total capital raised to over $58m, was led by World Innovation Lab with participation from John Doerr and current investors DBL Partners and SOSV / HAX. Rob Theis, General Partner at WiL, joined R-Zero’s Board of Directors as part of the round.
The company intends to use the funds to accelerate the development and deployment of its automated disinfection ecosystem.
Founded in early 2020 by Grant Morgan, CEO, R-Zero is a biosafety technology company dedicated to developing disinfection technologies to reduce the spread of all infectious diseases. Its first product, Arc [an IoT-enabled, whole-room UV disinfection device] is currently enabling a higher level of health safety for hundreds of thousands of people, across both public and private sector organizations, without the use of chemicals.
Informed by data science, built with AI, ML, and IoT connected hardware, R-Zero’s intelligent disinfection platform provides visibility, automation and smarter risk reduction within the indoor spaces where humans spend their time.
FinSMEs
18/06/2021